Quarterly ResultMay 8, 2026, 06:07 AM
Hyperliquid Strategies Q1 Net Income $152.5M; EPS $1.01
AI Summary
Hyperliquid Strategies Inc. reported a net income of $152.5 million, or $1.01 per diluted share, for the three months ended March 31, 2026. This was significantly driven by a $198.4 million unrealized gain on HYPE digital assets. The company also completed a business combination with Sonnet BioTherapeutics and Rorschach, and made a strategic investment in Guidant Bio Therapeutics Inc., acquiring a 40% common stock interest. Significant capital raises have alleviated prior going concern doubts.
Key Highlights
- Net income for the three months ended March 31, 2026, was $152.5 million.
- Diluted EPS for the three months ended March 31, 2026, was $1.01.
- Unrealized gain on HYPE digital assets was $198.4 million for the quarter.
- Total assets reached $810.4 million as of March 31, 2026.
- HYPE digital assets totaled $689.0 million as of March 31, 2026.
- Net cash provided by financing activities was $289.2 million for nine months.
- Acquired a 40% common stock interest in Guidant Bio Therapeutics Inc.
- Completed business combination with Sonnet BioTherapeutics and Rorschach.